FAST Congress joins forces with
High-Content Analysis & 3D Screening
for expanded coverage!
November 6-8, 2017 | Cambridge, MA
HighContentAnalysis.com
Wrapping up its third year, FAST: Functional Analysis & Screening Technologies Congress was host to 250+ Drug R&D teams dedicated to improving drug screening and safety using 3D cell culture, phenotypic screening, and cancer immunotherapy. Cambridge Healthtech Institute (CHI) would like to thank all the speakers, attendees, sponsors, and exhibitors for their participation.
2015 Event Stats:
- 250+ Delegates from 130+ Companies
- 60 Speakers
- 25 Posters Presented
- 15 Countries Represented
- 14 Exhibiting Companies
View the 2015 Attendee List
>Here’s what our attendees had to say about the congress:

If you missed our 2015 event, you can reserve a copy of the conference proceedings CD to access the speaker slides and poster abstracts our delegates received on-site.
Dinner Short Courses:
Coverage Includes:
- Organoids and Primary Organotypic 3D Culture in Drug Discovery
- Phenotypic Screening for New Target, Pathway and Mechanism-of-Action Discovery
- Phenotypic Screening Using Primary and Stem Cell-Derived Models
- Case Studies in Phenotypic Drug Discovery
- Engineering Functional Organ-on-a-Chip Models
- 3D Spheroid Models for Drug Screening
- Integrated Approach to in vitro Drug Discovery: Tissue Engineering Meets Systems Biology
- Microengineered 3D Models for Drug Safety Testing
- Phenotypic and High-Content Screening of 3D Models
- Cancer-on-a-Chip: Engineering 3D Models of Tumor Microenvironment
Featured Speakers:
Kevin E. Healy
Professor, Bioengineering, University of California, Berkeley
|
David C. Swinney
CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)
|
Per Erik Stromstedt
Director, Screening Sciences AstraZeneca
|
Jeffrey Morgan
Professor, Medical Science & Engineering Brown University
|
Hicham Alaoui
Director, Cellular Pharmacology Genentech
|
Linda G. Griffith
Professor, Biological Engineering, MIT
|
David Grainger
Professor, Pharmaceutical Chemistry University of Utah
|
Sophie A. Lelièvre
Director, 3D Cell Culture Core Facility Purdue University
|
David Tellers
Principal Scientist, Discovery Chemistry Merck
|
Anne Bang
Director, Cell-Based Disease Modeling and Screening, Sanford-Burnham-Prebys Medical Discovery Institute
|
Michael Shen
Professor, Medicine, Systems Biology Columbia University
|
|
For questions about the meeting, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute (CHI)
Email: juliab@healthtech.com
For sponsorship and exhibit sales information, please contact:
Angela Parsons
VP Business Development
Cambridge Healthtech Institute (CHI)
Phone: (+1) 781-972-5467
Email: aparsons@healthtech.com
For media and association partnerships, please contact:
James Prudhomme
Senior Marketing Manager
Cambridge Healthtech Institute (CHI)
Phone (+1) 781-972-5486
Email: jprudhomme@healthtech.com